OverviewChartNewsTraderScreen

Morgan Stanley Call 450 MDGL 20.1.../  DE000MG0D896  /

Stuttgart
06/06/2024  11:35:42 Chg.-0.030 Bid16:36:25 Ask16:36:25 Underlying Strike price Expiration date Option type
0.500EUR -5.66% 0.460
Bid Size: 15,000		 0.520
Ask Size: 15,000		 Madrigal Pharmaceuti... 450.00 USD 20/12/2024 Call
GlobeNewswire 14:00 Madrigal Pharmaceuticals Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra™ (resme...
GlobeNewswire 05/06 Madrigal Pharmaceuticals to Participate in the Goldman Sachs 45th Annual Global Healthcare Conferenc...
GlobeNewswire 29/05 Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) and Health Economics Outcomes R...
GlobeNewswire 22/05 Anavex Life Sciences Announces Expansion of Leadership Team
GlobeNewswire 07/05 Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
GlobeNewswire 24/04 Madrigal Statement on the Passing of Dr. Stephen Harrison
GlobeNewswire 23/04 Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, ...
GlobeNewswire 16/04 Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire 09/04 Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of...
GlobeNewswire 05/04 US Gastroenterologists Project Swift Uptake of Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) for ...
GlobeNewswire 04/04 GENFIT Reports Full-Year 2023 Financial Results and Provides Corporate Update
GlobeNewswire 03/04 Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire 19/03 Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering
GlobeNewswire 18/03 Madrigal Pharmaceuticals Announces Proposed Public Offering
GlobeNewswire 14/03 FDA’s Approval of Breakthrough NASH Treatment Opens Door for a Long-Neglected Patient Population
GlobeNewswire 14/03 Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Pati...
GlobeNewswire 06/03 Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire 05/03 Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Res...
GlobeNewswire 28/02 Madrigal Pharmaceuticals Appoints Mardi C. Dier as Chief Financial Officer
GlobeNewswire 28/02 Madrigal Pharmaceuticals Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Fi...
GlobeNewswire 21/02 Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire 08/02 Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in th...
GlobeNewswire 06/02 Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire 29/01 Madrigal Pharmaceuticals Announces Additions to Its Leadership Team
GlobeNewswire 22/01 Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)